Murphy Pohlad Asset Management LLC reduced its stake in shares of Pfizer, Inc. (NYSE:PFE) by 2.6% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 74,742 shares of the biopharmaceutical company’s stock after selling 1,979 shares during the period. Pfizer accounts for about 1.9% of Murphy Pohlad Asset Management LLC’s holdings, making the stock its 18th largest position. Murphy Pohlad Asset Management LLC’s holdings in Pfizer were worth $2,556,000 as of its most recent SEC filing.
A number of other hedge funds have also modified their holdings of PFE. Orbimed Advisors LLC raised its stake in shares of Pfizer by 46.3% in the fourth quarter. Orbimed Advisors LLC now owns 5,167,900 shares of the biopharmaceutical company’s stock valued at $167,853,000 after buying an additional 1,635,700 shares during the last quarter. Paulson & CO. Inc. acquired a new stake in shares of Pfizer during the fourth quarter valued at approximately $11,439,000. E&G Advisors LP raised its stake in shares of Pfizer by 6.8% in the first quarter. E&G Advisors LP now owns 62,258 shares of the biopharmaceutical company’s stock valued at $2,130,000 after buying an additional 3,940 shares during the last quarter. Prentiss Smith & Co. Inc. raised its stake in shares of Pfizer by 1.7% in the first quarter. Prentiss Smith & Co. Inc. now owns 14,948 shares of the biopharmaceutical company’s stock valued at $511,000 after buying an additional 250 shares during the last quarter. Finally, Carroll Financial Associates Inc. raised its stake in shares of Pfizer by 33.9% in the first quarter. Carroll Financial Associates Inc. now owns 197,820 shares of the biopharmaceutical company’s stock valued at $6,767,000 after buying an additional 50,045 shares during the last quarter. 69.97% of the stock is currently owned by institutional investors.
Shares of Pfizer, Inc. (NYSE:PFE) opened at 33.35 on Monday. The firm has a 50-day moving average price of $32.80 and a 200-day moving average price of $33.17. Pfizer, Inc. has a 52-week low of $29.83 and a 52-week high of $37.39. The stock has a market cap of $199.03 billion, a P/E ratio of 28.07 and a beta of 1.01.
Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, May 2nd. The biopharmaceutical company reported $0.69 EPS for the quarter, beating analysts’ consensus estimates of $0.67 by $0.02. The firm had revenue of $12.78 billion for the quarter, compared to analysts’ expectations of $13.09 billion. Pfizer had a return on equity of 23.68% and a net margin of 13.76%. Pfizer’s quarterly revenue was down 1.7% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.67 EPS. On average, analysts anticipate that Pfizer, Inc. will post $2.55 EPS for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Friday, September 1st. Shareholders of record on Friday, August 4th will be paid a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a dividend yield of 3.84%. The ex-dividend date is Wednesday, August 2nd. Pfizer’s dividend payout ratio is presently 108.48%.
WARNING: This piece was reported by WKRB News and is the sole property of of WKRB News. If you are viewing this piece on another publication, it was stolen and republished in violation of US and international copyright law. The correct version of this piece can be read at https://www.wkrb13.com/markets/2284136/pfizer-inc-nysepfe-stake-decreased-by-murphy-pohlad-asset-management-llc.html.
Several analysts have commented on PFE shares. Barclays PLC set a $38.00 price objective on Pfizer and gave the company a “buy” rating in a report on Thursday, March 16th. Jefferies Group LLC restated a “neutral” rating and issued a $35.00 target price (up previously from $34.00) on shares of Pfizer in a research report on Thursday, April 13th. BidaskClub upgraded Pfizer from a “strong sell” rating to a “sell” rating in a research report on Friday, June 23rd. BMO Capital Markets restated a “hold” rating and issued a $33.00 target price on shares of Pfizer in a research report on Tuesday, March 21st. Finally, Sanford C. Bernstein set a $35.00 target price on Pfizer and gave the company a “buy” rating in a research report on Monday, March 13th. Two analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of $37.32.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer, Inc. (NYSE:PFE).
This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2284136/pfizer-inc-nysepfe-stake-decreased-by-murphy-pohlad-asset-management-llc.html
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.